Risk-Based Nurse-Managed Personalized Heart Failure Interventions: The ALLEVIATE-HF Trial.

Area of Science:

• Cardiology
• Medical Devices
• Digital Health

Background:

• Early identification of worsening heart failure (HF) is crucial for improving patient outcomes.
• Insertable cardiac monitors (ICMs) offer continuous physiological monitoring for HF patients.

Purpose of the Study:

• To evaluate the safety and efficacy of an ICM-based system for detecting high-risk HF events.
• To assess if centrally managed, nurse-facilitated diuretic interventions improve HF outcomes.

Main Methods:

• Randomized trial comparing ICM with HF risk-status software and protocolized diuretic intervention versus standard care.
• Primary safety endpoint: intervention-related serious adverse events. Primary efficacy endpoint: a 5-component composite including mortality, HF hospitalizations, and functional status.
• Analysis using win ratio for the composite endpoint.

Main Results:

• 711 participants randomized; primary composite endpoint did not differ significantly (win ratio: 0.79, P=0.06).
• The intervention was safe, with a low serious adverse event rate (0.32%).
• Numerically higher cardiovascular death and HF events in the intervention group (HR: 1.43, P=0.091).

Conclusions:

• ICM-based risk detection combined with coordinated diuretic intervention was safe.
• The tested strategy did not significantly improve the primary composite outcome in the ALLEVIATE-HF study.
• Further research may explore optimized implementation strategies for ICM-guided HF management.